SEC Form 4 · accession 0001123292-17-000213
Recro Pharma, Inc. · REPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Geraldine Henwood
Officer — Chief Executive Officer · Director
Period of report
Jan 18, 2017
Accepted (ET)
Jan 20, 2017 · 3:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001588972
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $7.33 | Jan 18, 2017 | A | 144,700 | A | — | Jan 18, 2027 | Common Stock | 144,700 | 144,700 | D |
| Restricted Stock UnitsF2,F3 | — | Jan 18, 2017 | A | 20,000 | A | — | — | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1The stock option vests in equal monthly installments over 48 months, beginning on the date that is one month from the date of grant, subject to continued employment with the Company.
- F2Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
- F3The restricted stock units vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.